Simpson's 2.7% revenue growth & 4.8% EPS decline signal risk. Fair 19.3x P/E offers little upside.
Pharma stocks dip as Trump eyes 100% tariffs on some drugs. Investors eye valuation shifts.
Select Water Solutions surged 42% but trades at 44.7x P/E. Subscale biz, weak margins & FCF signal risk.
Tech ETF down 16% offers a discount. Diversified holdings mitigate risk, aiming for long-term recovery.
Kyndryl's 58% drop & negative ROIC signal risk despite cheap P/E. Avoid.
S&P 500's 28x P/E looks frothy. VXUS offers global diversification at 18x P/E, with 15.9% avg. earnings growth.
Lindblad Expeditions' 42.5% rally may be over. Stretched valuation (123.6x P/E) & slowing revenue growth signal caution.
Sponsored
Must Read